Dag E.,Elazig Research and Education Hospital |
Aydin S.,Firat University |
Ozkan Y.,Firat University |
Erman F.,Firat University |
And 2 more authors.
Peptides | Year: 2010
This study was designed to measure the levels of chromogranin A (CgA), ghrelin and obestatin in serum and saliva (including CgA expression in healthy tissue) in epileptic patients to determine any significant differences between these patients and healthy controls. Samples were obtained from a total of 91 subjects: 10 newly-diagnosed primary generalized epilepsy (PGE) patients who had started treatment with valproic acid and phenytoin for seizure control; 18 PGE patients who were previously and currently receiving treatment with valproic acid and phenytoin for seizure control; 37 patients with partial epilepsy (PE) (simple, n=17 or complex, n=20) who had been and were still being treated with carbazebime for seizures; and 26 healthy controls. CgA immunoreactivity in healthy salivary gland was analyzed by immunohistochemistry and ELISA. The levels of CgA, total ghrelin and obestatin in serum and saliva were measured by ELISA. The results revealed that normal salivary gland produces its own CgA. Before treatment, CgA levels in saliva and serum were significantly greater in patients newly-diagnosed with PGE than controls. Ghrelin and CgA concentrations were also greater in PGE patients previously or currently treated with drugs, and in patients with simple or complex partial epilepsy (PE) previously or currently treated with drugs, than in healthy normal controls. In conclusion, salivary concentrations of CgA, ghrelin and obestatin were similar to their serum levels, so saliva might be a desirable alternative to serum for measuring these hormones because it is easy and painless to collect. © 2010 Elsevier Inc.
Celik A.,Elazig Education and Research Hospital
Journal of Atherosclerosis and Thrombosis | Year: 2011
Aim: The increase of tenascin-C levels after myocardial infarction has been demonstrated by previous studies. The relationship between tenascin-C and the grade of stenosis in the infarct-related coronary artery was indeterminate. The aim of this study was to evaluate the relationship between tenascin-C levels and total occlusion after acute myocardial infarction. Method: Fifty-nine patients with subacute anterior myocardial infarction were divided into two groups according to their having a totally or sub totally occluded left anterior descending artery Plasma tenascin-C, troponin I, CK-MB, uric acid, mean platelet volume, and lipid profile levels were also measured. Results: The history of the smoking rate, hypertension and diabetes mellitus were similar in both groups. Hemoglobin, mean platelet volume, serum creatinine, CK-MB, troponin I, serum lipid profile and uric acid levels were similar in the two groups. The CRP and tenascin-C levels were significantly higher in the total occlusion group. Tenascin-C levels were highest in patients with proximal LAD total occlusion and lowest in patients with subtotal LAD occlusion. The tenascin-C levels were correlated with the grade of stenosis (r= 0.602, p< 0.001). Conclusion: This study demonstrates that higher tenascin-C levels were related with the total occlusion and inflammation after MI.
Dogantekin E.,Firat University |
Dogantekin A.,Firat University |
Avci D.,Bahcelievler Primary Education School |
Avci L.,Elazig Education and Research Hospital
Digital Signal Processing: A Review Journal | Year: 2010
In this study, an intelligent diagnosis system for diabetes on Linear Discriminant Analysis (LDA) and Adaptive Network Based Fuzzy Inference System (ANFIS): LDA-ANFIS is presented. The structure of this LDA-ANFIS intelligent system for diagnosis of diabetes is composed by two phases: The Linear Discriminant Analysis (LDA) phase and classificiation by using ANFIS classifier phase. In first phase, Linear Discriminant Analysis (LDA) is used to separate features variables between healthy and patient (diabetes) data. In second phase, the healthy and patient (diabetes) features obtained in first phase are given to inputs of ANFIS classifier. The correct diagnosis performance of the LDA-ANFIS intelligent system is calculated by using sensitivity and specificity analysis, classification accuracy and confusion matrix respectively. The classification accuracy of this LDA-ANFIS intelligent system was obtained about 84.61%. © 2009 Elsevier Inc. All rights reserved.
Ucak H.,Elazig Education and Research Hospital |
Kandi B.,Firat University |
Cicek D.,Firat University |
Halisdemir N.,Firat University |
Dertlioglu S.B.,Harran University
Journal of Dermatological Treatment | Year: 2012
Background: Alopecia areata (AA) is a non-scarring hair loss. Objective: We aimed the comparison of clobetasol propionate and pimecrolimus efficiency and tolerability in the treatment of AA. Methods: The study included a total of 100 consecutive patients with AA. Patients were randomized into four groups. 30 patients used 1% pimecrolimus cream, 30 patients used 0.05% clobetasol propionate cream, 20 patients used petrolatum as placebo. Scalp of 20 patients was divided into two equal areas and one area was treated with 1% pimecrolimus cream and the other area with 0.05% clobetasol propionate cream. Results: At week 12 of treatment, the recovery rate of the pimecrolimus group was 53.73 ± 44.49 and the recovery score was 3.63 ± 2.07; that of the clobetasol propionate group was 47.00 ± 44.80 and the recovery score was 3.33 ± 2.20; that of the placebo group was 35.50 ± 40.53 and the recovery score was 2.75 ± 1.88. There was no statistically significant difference among the groups in terms of the percentage of recovery and the recovery score (p < 0.05). Conclusion: In conclusion, we detected that topical pimecrolimus treatment is as effective as topical corticosteroids and is superior to topical corticosteroids in terms of side effects in the treatment of AA. © 2012 Informa Healthcare USA on behalf of Informa UK Ltd.
Acar M.,Ear |
Cingi C.,Eskiehir Osmangazi University |
Sakallioglu O.,Elazig Education and Research Hospital |
San T.,Istanbul Medeniyet University |
And 2 more authors.
American Journal of Rhinology and Allergy | Year: 2013
Background: Allergic rhinitis (AR) and obstructive sleep apnea syndrome (OSAS) are worldwide prevalent diseases. These diseases impair patient quality of life. The aim of this study was to investigate and compare the efficacy of treatment of AR on OSAS by objective and subjective methods. Methods: The study group was composed of 80 OSAS patients with AR between the ages of 30 and50 years. The patients were admitted with the complaint of snoring, and they were asked about AR-related symptoms (nasal discharge, nasal itching, sneeze, and nasal obstruction). Daytime somnolence was measured by the Epworth sleepiness scale (ESS). Sleep parameters on polysomnography tests before and after treatment were compared, and the effects of different AR treatment protocols on sleep quality were evaluated. Results: When pretreatment and posttreatment apnea-hypopnea index (AHI) values of the groups were compared, the most significant difference was observed in the nasal steroid (Ns) + antihistamine (Ah) group (p < 0.05). The ESS results were significantly decreased in the Ns and Ns + Ah groups after treatment (p < 0.05). AHI oxygen saturation <90% were significantly decreased in the Ns and Ns + Ah groups after treatment (p < 0.05). Conclusion: Nasal obstruction due to nasal congestion causes increases in airway resistance and can lead to development of OSAS. We concluded that treating AR with Ns has both positive effects on OSAS and daily activity. However, adding Ah to this treatment did not show improved effects compared with placebo treatment. Copyright © 2013, OceanSide Publications, Inc., U.S.A.